Please login to the form below

Not currently logged in
Email:
Password:

Nabriva Therapeutics adds Will Sargent to team

Join as VP of commercial strategy and investor relations
Will Sargent Nabriva Therapeutics

Nabriva Therapeutics has appointed Will Sargent in the newly created position of vice president of commercial strategy and investor relations.

Sargent has over twenty years of experience in the biopharmaceutical industry, including multiple product and line extension launches. His most recent position was as VP of the orthopaedic business unit at Auxilium Pharmaceuticals.

Nabriva is currently moving rapidly to advance its lead product, lefamulin, into phase III clinical studies which are expected to begin enrolling in 2015 and 2016.

He said: “I am excited to join this talented and dedicated team focused on advancing a novel, targeted antibiotic therapy that can impact patients' lives by addressing an unmet medical need.

“I look forward to applying my experience toward the successful development and implementation of the lefamulin commercial strategy and expansion of corporate communications.”

Dr Colin Broom, CEO of Nabriva, added: “Will's strategic focus, experience and breadth of knowledge will help us plan and execute toward our commercial path goals.”

14th October 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics